Exelixis
EXEL
#1694
Rank
S$15.47 B
Marketcap
S$57.49
Share price
-0.02%
Change (1 day)
19.16%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : S$0.85 Billion

According to Exelixis's latest financial reports the company's total liabilities are S$0.85 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31S$0.95 B6.72%
2023-12-31S$0.89 B14.63%
2022-12-31S$0.78 B42.54%
2021-12-31S$0.54 B60.52%
2020-12-31S$0.34 B26.88%
2019-12-31S$0.26 B46.16%
2018-12-31S$0.18 B-62.81%
2017-12-31S$0.49 B-32.42%
2016-12-31S$0.73 B9.51%
2015-12-31S$0.66 B15.62%
2014-12-31S$0.57 B4.54%
2013-12-31S$0.55 B6.63%
2012-12-31S$0.51 B32.51%
2011-12-31S$0.39 B-48.35%
2010-12-31S$0.75 B6.59%
2009-12-31S$0.71 B8.73%
2008-12-31S$0.65 B39.33%
2007-12-31S$0.46 B0.56%
2006-12-31S$0.46 B1.92%
2005-12-31S$0.45 B16.8%
2004-12-31S$0.39 B17.72%
2003-12-31S$0.33 B17.79%
2002-12-31S$0.28 B39.83%
2001-12-31S$0.20 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
GlaxoSmithKline
GSK
S$79.41 B 9,145.63%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
S$85.56 B 9,861.14%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
S$100.61 B 11,612.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$101.45 B 11,711.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
S$104.34 B 12,047.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
S$147.13 B 17,028.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$149.85 B 17,345.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
S$54.85 M-93.61%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
S$93.8 M-89.08%๐Ÿ‡บ๐Ÿ‡ธ USA